Ocera Therapeutics Inc. (NASDAQ:OCRX) shares rose 21% during trading on Thursday . The stock traded as high as $2.56 and last traded at $2.48, with a volume of 77,798 shares. The stock had previously closed at $2.05.

OCRX has been the subject of several analyst reports. Zacks Investment Research downgraded Ocera Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday. Brean Capital restated a “buy” rating on shares of Ocera Therapeutics in a research note on Tuesday, April 12th.

The firm’s market capitalization is $55.61 million. The stock’s 50 day moving average price is $2.30 and its 200 day moving average price is $2.75.

Ocera Therapeutics (NASDAQ:OCRX) last posted its quarterly earnings results on Friday, April 29th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by $0.03. Analysts forecast that Ocera Therapeutics Inc. will post ($1.39) earnings per share for the current year.

An institutional investor recently raised its position in Ocera Therapeutics stock. Turner Investments L.P. raised its stake in Ocera Therapeutics Inc. (NASDAQ:OCRX) by 29.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 673,487 shares of the biopharmaceutical company’s stock after buying an additional 152,210 shares during the period. Turner Investments L.P. owned about 3.28% of Ocera Therapeutics worth $2,101,000 at the end of the most recent reporting period.

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.